Casdozokitug is a monoclonal antibody commercialized by Coherus BioSciences, with a leading Phase II program in Squamous Non-Small Cell Lung Carcinoma. According to Globaldata, it is involved in 6 clinical trials, of which 3 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Casdozokitug’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Casdozokitug is expected to reach an annual total of $27 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Casdozokitug Overview

Casdozokitug (SRF-388) is under development for the treatment of solid tumors including renal cell cancer, non-small-cell lung cancer, squamous cell non-small-cell lung carcinoma, hepatocellular cancer and metastatic hepatocellular cancer. It is a monoclonal antibody acts by targeting cytokine IL-27. It is administered through intravenous route.

It was also under development for the treatment of lung cancer.

Coherus BioSciences Overview

Coherus BioSciences (Coherus) is a commercial-stage biopharmaceutical company that focuses on research, development and commercialization of innovative immunotherapies to treat cancer. Its pipeline products include LOQTORZI (toripalimab-tpzi), a novel PD-1 inhibitor, that treats Nasopharyngeal Carcinoma; Casdozokitug is an investigational recombinant human IgG1 monoclonal antibody for Hepatocellular Carcinoma and Non-Small Cell Lung Cancer; CHS-114 and CHS-1000, which targets Solid Tumors. The company also develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor and YUSIMRY, a biosimilar to Humiram which treats inflammatory diseasesCoherus is headquartered in Redwood City, California, the US.
The company reported revenues of (US Dollars) US$257.2 million for the fiscal year ended December 2023 (FY2023), an increase of 21.9% over FY2022. The operating loss of the company was US$203.2 million in FY2023, compared to an operating loss of US$263.1 million in FY2022. The net loss of the company was US$237.9 million in FY2023, compared to a net loss of US$291.8 million in FY2022. The company reported revenues of US$77.1 million for the first quarter ended March 2024, a decrease of 15.8% over the previous quarter.

For a complete picture of Casdozokitug’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.